Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes

Mallat, Ziad; Steg, Philippe Gabriel; Bénessiano, Joëlle; Tanguy, Marie‐Laure; Fox, Keith A.A.; Collet, Jean‐Philippe; Dabbous, O.; Henry, Patrick; Carruthers, Kathryn; Dauphin, Anne; Arguelles, Carla Sibella; Masliah, J.; Hugel, Bénédicte; Montalescot, Gilles; Freyssinet, Jean‐Marie; Asselain, Bernard; Tedgui, Alain

doi:10.1016/j.jacc.2005.06.056

Cited by 103 publications

(70 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, increased circulating level of phospholipase A2, coded by PLA2GA2, has been reported as a significant risk factor for CAD (17). It has also been suggested to function as a strong predictor of recurrent events in patients with acute coronary syndromes such as myocardial infarction (21). The Pla2g4a gene, coding for a cytosolic form of phospholipase A2, has so far been shown to be necessary for normal growth, as well as playing an important role for pathological stress-induced hypertrophy of the mouse heart (10).…”

Section: Discussionmentioning

confidence: 99%

Comparison of human cardiac gene expression profiles in paired samples of right atrium and left ventricle collected in vivo

Asp

Synnergren

Jönsson

et al. 2012

Physiological Genomics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Comparison of human cardiac gene expression profiles in paired samples of right atrium and left ventricle collected in vivo

Asp

Synnergren

Jönsson

et al. 2012

Physiological Genomics

View full text Add to dashboard Cite

“…Human sPLA 2 s have been classified into groups IB, IIA, IID, IIE, IIF, III, V, X, XIIA and XIIB according to their structural properties (Laye and Gill, 2003;Rouault et al, 2003;Murakami et al, 2005;Cummings, 2007). Several of these proteins have recently been proposed either as biomarkers of pathologies (Smith et al, 2003;Mallat et al, 2005;Wootton et al, 2007) or as therapeutic targets (Laye and Gill, 2003;Cummings, 2007;Henderson et al, 2007). These enzymes have the capacity to generate biologically active lipid mediators such as lysophosphatidic acid (LPA) and arachidonic acid (AA), which can be further converted into prostaglandin E 2 (PGE 2 ).…”

mentioning

confidence: 99%

Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate

Wendum

Greenspan

et al. 2008

Br J Cancer

View full text Add to dashboard Cite

Recent studies suggest that secreted phospholipases A 2 (sPLA 2 s) represent attractive potential tumour biomarkers and therapeutic targets for various cancers. As a first step to address this issue in human colorectal cancer, we examined the expression of the full set of sPLA 2 s in sporadic adenocarcinomas and normal matched mucosa from 21 patients by quantitative PCR and immunohistochemistry. In normal colon, PLA2G2A and PLA2G12A were expressed at high levels, PLA2G2D, PLA2G5, PLA2G10 and PLA2G12B at moderate levels, and PLA2G1B, PLA2G2F and PLA2G3 at low levels. In adenocarcinomas from left and right colon, the expression of PLA2G3 was increased by up to 40-fold, while that of PLA2G2D and PLA2G5 was decreased by up to 23-and 14-fold. The variations of expression for sPLA 2 -IID, sPLA 2 -III and sPLA 2 -V were confirmed at the protein level. The expression pattern of these sPLA 2 s appeared to be linked respectively to the overexpression of interleukin-8, defensin a6, survivin and matrilysin, and downregulation of SFRP-1 and RLPA-1, all these genes being associated to colon cancer. This original sPLA 2 profile observed in adenocarcinomas highlights the potential role of certain sPLA 2 s in colon cancer and suggests that sPLA 2 -III might be a good candidate as a novel biomarker for both left and right colon cancers.

show abstract

“…On the other hand, atherosclerosis itself is increasingly recognized as a localized inflammatory condition within the vessel wall (12,13). The pathophysiological significance of sPLA 2 in this respect is underlined by studies demonstrating increased circulating plasma levels of sPLA 2 to be predictive for acute coronary events (14)(15)(16).…”

mentioning

confidence: 99%

Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion

Tietge

Nijstad

Havinga

et al. 2008

Journal of Lipid Research

View full text Add to dashboard Cite

High density lipoprotein cholesterol represents a major source of biliary cholesterol. Secretory phospholipase A 2 (sPLA 2 ) is an acute phase enzyme mediating decreased plasma HDL cholesterol levels. Clinical studies reported a link between increased sPLA 2 expression and the presence of cholesterol gallstones. The aim of our study was to investigate whether the overexpression of human sPLA 2 in transgenic mice affects biliary cholesterol secretion and gallstone formation. Liver weight (P , 0.01) and hepatic cholesterol content (P , 0.01) were significantly increased in sPLA 2 transgenic mice compared with controls as a result of increased scavenger receptor class B type I (SR-BI)-mediated hepatic selective uptake of HDL cholesterol (P , 0.01), whereas hepatic SR-BI expression remained unchanged. However, biliary cholesterol secretion as well as fecal neutral sterol and fecal bile salt excretion remained unchanged in sPLA 2 transgenic mice. Furthermore, gallstone prevalence in response to a lithogenic diet was identical in both groups.These data demonstrate that i) increased flux of cholesterol from HDL into the liver via SR-BI as a result of phospholipase modification of the HDL particle translates neither into increased biliary and fecal sterol output nor into increased gallstone formation, and ii) increased sPLA 2 expression in patients with cholesterol gallstones might be a consequence rather than the under-

show abstract

Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes

Abstract: A single measurement of plasma sPLA2 activity at the time of enrollment provides strong independent information to predict recurrent events in patients with ACS.

Cited by 103 publications

References 49 publications

Comparison of human cardiac gene expression profiles in paired samples of right atrium and left ventricle collected in vivo

Comparison of human cardiac gene expression profiles in paired samples of right atrium and left ventricle collected in vivo

Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate

Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion

Contact Info

Product

Resources

About